SCHEMBL10061669

SCHEMBL10061669

C=C1NCc2cc(NC3CCOCC3)ccc2N1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 4/20 0.36
MAPK1 P28482 4/20 0.35
PARP14 Q460N5 1/20 0.34
BACE1 P56817 1/20 0.34
BACE2 Q9Y5Z0 1/20 0.34
PLK4 O00444 1/20 0.33
AXL P30530 4/20 0.32
ETV6 P41212 2/20 0.32
LMNA P02545 1/20 0.32
CSF1R P07333 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
APAF1 O14727 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
BLM P54132 1/20 0.32
KMT2A Q03164 1/20 0.32
HSD17B10 Q99714 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
SYK P43405 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10061741 0.71 POLB (0.48) AXLCSF1R
Hydrochloric Acid SCHEMBL31013922 0.67 DRD2 (0.40) MAPK1BACE1BACE2
SCHEMBL657241 0.65 LMNA (0.45) LRRK2MAPK1PARP14BACE1BACE2
SCHEMBL30089564 0.65 MAPK1 (0.53) LRRK2MAPK1PLK4LMNA
SCHEMBL18129725 0.65 KDM1A (0.51) LRRK2MAPK1PLK4LMNAMEN1
SCHEMBL23247149 0.65 PLK4 (0.54) LRRK2MAPK1BACE1BACE2PLK4
SCHEMBL488077 0.65 MAPK1 (0.44) MAPK1BACE1BACE2PLK4LMNA
SCHEMBL178453 0.65 MAPK1 (0.53) LRRK2MAPK1PLK4LMNAMAPT
SCHEMBL657242 0.65 MAPK1 (0.44) LRRK2MAPK1PARP14PLK4LMNA
SCHEMBL632436 0.64 MAPK1 (0.52) LRRK2MAPK1PLK4LMNACSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207179-B2 Substituted indolines as tyrosine kinase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-26 US disclosed
US-20100222331-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222331-A1 NEW COMPOUNDS CCNA1, CCNY, MKI67 LRRK2 1817/4885MAPK1 492/4885PARP14 1018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.